Quantitative benefit-risk assessment by MCDA of the quadrivalent HPV vaccine for preventing anal cancer in males.

Autor:	Marcelon L; a Epidemiology Department , Sanofi Pasteur MSD , Lyon Cedex 07 , France., Verstraeten T; a Epidemiology Department , Sanofi Pasteur MSD , Lyon Cedex 07 , France.; b Epidemiology and Pharmacovigilance Consulting and Services , P95 , Leuven , Belgium., Dominiak-Felden G; a Epidemiology Department , Sanofi Pasteur MSD , Lyon Cedex 07 , France., Simondon F; a Epidemiology Department , Sanofi Pasteur MSD , Lyon Cedex 07 , France.
Jazyk:	angličtina
Zdroj:	Expert review of vaccines [Expert Rev Vaccines] 2016; Vol. 15 (1), pp. 139-48. Date of Electronic Publication: 2015 Nov 02.
DOI:	10.1586/14760584.2016.1107480
Abstrakt:	Objectives: To quantify the benefit-risk (BR) balance of the quadrivalent human papillomavirus (qHPV) vaccine for use in males, including anal cancer prevention, by using the multicriteria decision analysis (MCDA). Methods: Value tree and an effect table were compiled using relevant qHPV vaccine efficacy/safety data. An expert panel validated the final model inputs. Results: On a scale of 0-100, the MCDA qHPV vaccine score (66) was superior to the no vaccination score (46), indicating a more favorable BR balance for the qHPV vaccine. Significant changes in weight of individual outcomes were needed to change BR balance in sensitivity analyses. The qHPV vaccine maintained a better BR profile in all alternative models. Conclusions: MCDA can be used to transparently evaluate BR balance of vaccines. The qHPV vaccine had a favorable BR balance in males. Including anal cancer as a new indication further improves the BR profile of the qHPV vaccine.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu